Circular Genomics Secures $15M Series A to Advance Circular RNA Therapies

Why It Matters

The infusion of $15 M positions Circular Genomics to fast‑track novel RNA therapeutics, potentially reshaping treatment paradigms in high‑unmet‑need neuro‑psychiatric markets.

Key Takeaways

• $15M Series A led by Mountain Group Partners
• Focus on circular RNA for neurology, psychiatry
• ADDF participation signals Alzheimer’s focus
• Funds target pre‑clinical validation and biomarker expansion
• Positions firm against traditional small‑molecule pipelines

Pulse Analysis

Circular RNA has emerged as a compelling modality for drug discovery, offering enhanced stability and tissue specificity compared with linear RNA. Investors are increasingly gravitating toward platforms that can unlock these advantages, especially in neuro‑degenerative and psychiatric disorders where conventional approaches have stalled. Circular Genomics’ $15 million raise underscores the market’s confidence in its proprietary technology and reflects a broader shift toward RNA‑centric therapeutics within the biotech funding ecosystem.

The involvement of the Alzheimer’s Drug Discovery Foundation (ADDF) adds strategic weight, signaling that the company’s pipeline aligns with critical gaps in Alzheimer’s and related cognitive disorders. By leveraging circular RNA to modulate gene expression, Circular Genomics aims to develop disease‑modifying candidates that could outperform symptomatic treatments. This approach also dovetails with emerging biomarker strategies, enabling more precise patient stratification and potentially accelerating regulatory pathways for high‑risk, high‑reward indications.

From an investment perspective, the round diversifies the capital base with both venture and disease‑focused funds, positioning Circular Genomics to compete with larger RNA players while maintaining agility. The capital infusion will fund pre‑clinical studies, scale manufacturing capabilities, and expand the company’s intellectual property portfolio. If successful, the firm could attract partnership deals with major pharma, catalyzing further funding rounds and establishing a foothold in the rapidly expanding RNA therapeutics market.

Deal Summary

San Diego‑based Circular Genomics announced a $15 million Series A round led by Mountain Group Partners, with participation from Poplar Grove Investors, HIP Fund and the Alzheimer’s Drug Discovery Foundation. The funding will be used to develop its circular RNA‑based precision medicine platform for neurology and psychiatry.